LIXT
Lixte Biotechnology Holdings Inc
$
3.410
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
3.790
Open
3.290
VWAP
3.59
Vol
131.03K
Mkt Cap
15.55M
Low
3.0801
Amount
470.00K
EV/EBITDA(TTM)
--
Total Shares
2.25M
EV
14.21M
EV/OCF(TTM)
--
P/S(TTM)
--
Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. The Company’s inhibitors of protein phosphatases have significant therapeutic potential for a broad range of cancers. It is focused on the clinical development of a specific protein phosphatase inhibitor, LB-100. The LB-100 series has activity against a broad spectrum of common and rarer human cancers in cell culture systems. In addition, lead compounds of the LB-100 series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue.
Show More
Valuation Metrics
The current forward P/E ratio for Lixte Biotechnology Holdings Inc (LIXT.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Lixte Biotechnology Holdings Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q2
0.00
Total Revenue
FY2025Q2
YoY :
-23.22%
-774.81K
Operating Profit
FY2025Q2
YoY :
-23.27%
-775.67K
Net Income after Tax
FY2025Q2
YoY :
-35.56%
-0.29
EPS - Diluted
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
LIXT News & Events
Events Timeline
2025-08-18 (ET)
2025-08-18
08:11:25
Lixte Biotechnology Shares Recent Developments in Corporate Activities
2025-08-13 (ET)
2025-08-13
07:43:36
Lixte Biotechnology updates treasury policy to include cryptocurrency
2025-07-16 (ET)
2025-07-16
08:09:27
Lixte regains compliance with Nasdaq's Continued Listing requirements
Sign Up For More Events
Sign Up For More Events
News
9.0
08-19Newsfilter24/7 Market Update: LIXTE Biotechnology Focus - Reevaluating the "Excessive Benefits" Approach for LB-100
9.0
08-19Yahoo Finance24/7 Market Update: LIXTE Biotechnology Focus - Reevaluating the "Excessive Benefits" Approach for LB-100
9.0
08-15Yahoo Finance24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025
Sign Up For More News
People Also Watch
FAQ
What is Lixte Biotechnology Holdings Inc (LIXT) stock price today?
The current price of LIXT is 3.41 USD — it has increased 3.02 % in the last trading day.
What is Lixte Biotechnology Holdings Inc (LIXT)'s business?
What is the price predicton of LIXT Stock?
What is Lixte Biotechnology Holdings Inc (LIXT)'s revenue for the last quarter?
What is Lixte Biotechnology Holdings Inc (LIXT)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Lixte Biotechnology Holdings Inc (LIXT)'s fundamentals?
How many employees does Lixte Biotechnology Holdings Inc (LIXT). have?